Atypical Chronic Myeloid Leukemia

Atypical Chronic Myeloid Leukemia (aCML), also known as Chronic Myelomonocytic Leukemia 2 (CMML-2), is a rare type of leukemia that does not exhibit the Philadelphia chromosome, a genetic abnormality typically found in classical chronic myeloid leukemia (CML). This condition is characterized by an increased number of monocytes in the blood and bone marrow, alongside features that distinguish it from other myeloproliferative disorders and myelodysplastic syndromes.

Etiology[edit | edit source]

The exact cause of aCML remains unclear. However, it is believed to involve genetic mutations that affect the normal development and function of white blood cells. Unlike classical CML, aCML does not involve the BCR-ABL1 fusion gene associated with the Philadelphia chromosome.

Symptoms[edit | edit source]

Patients with aCML may experience a range of symptoms, including fatigue, fever, weight loss, and splenomegaly (enlarged spleen). Due to the overproduction of abnormal white blood cells, individuals may also suffer from frequent infections.

Diagnosis[edit | edit source]

Diagnosis of aCML involves a combination of clinical examination, blood tests, and bone marrow analysis. Blood tests typically show elevated white blood cell counts with a significant increase in monocytes. Bone marrow biopsy is crucial for confirming the diagnosis, revealing an increased number of immature white cells and monocytes.

Treatment[edit | edit source]

Treatment options for aCML are limited and primarily focus on managing symptoms and improving quality of life. Therapeutic strategies may include chemotherapy, targeted therapy, and in some cases, hematopoietic stem cell transplantation. The choice of treatment depends on various factors, including the patient's overall health, age, and the progression of the disease.

Prognosis[edit | edit source]

The prognosis for patients with aCML is generally poor, with a median survival time of approximately 20-30 months from diagnosis. The disease tends to progress rapidly, and patients are at high risk of transforming into acute myeloid leukemia (AML).

Research[edit | edit source]

Ongoing research is focused on understanding the genetic and molecular mechanisms underlying aCML to develop more effective treatments. Clinical trials are exploring the use of new targeted therapies and combination treatments to improve outcomes for patients with this challenging condition.